Gene Biotherapeutics, Inc.
CRXM · OTC
12/31/2020 | 9/30/2020 | 6/30/2020 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | -$1 | $0 |
| Operating Expenses | $1 | $0 | -$0 | $0 |
| Operating Income | -$1 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | -$0 | $1 | -$0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EPS | -0.019 | -0.015 | 0.03 | -0.01 |
| % Growth | -26% | -150% | 400% | – |
| EPS Diluted | -0.019 | -0.015 | 0.004 | -0.01 |
| Weighted Avg Shares Out | 24 | 24 | 15 | 14 |
| Weighted Avg Shares Out Dil | 24 | 24 | 19 | 14 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |